Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study
{{output}}
Background: Clinical trials that demonstrated sodium-glucose cotransporter-2 inhibitors (SGLT2i) benefits in patients with type 2 diabetes (T2D) excluded patients treated with glucocorticoids. It is unknown whether SGLT2i are saf... ...
